

Gary D Hammer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/881974/publications.pdf>

Version: 2024-02-01

112
papers

11,899
citations

31976

53
h-index

27406

106
g-index

129
all docs

129
docs citations

129
times ranked

13129
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018, 173, 321-337.e10.	28.9	2,111
2	Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 364-389.	3.6	1,166
3	Adrenocortical Carcinoma. <i>Endocrine Reviews</i> , 2014, 35, 282-326.	20.1	671
4	Wilms' Tumor 1 and Dax-1 Modulate the Orphan Nuclear Receptor SF-1 in Sex-Specific Gene Expression. <i>Cell</i> , 1998, 93, 445-454.	28.9	546
5	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016, 29, 723-736.	16.8	482
6	Phosphorylation of the Nuclear Receptor SF-1 Modulates Cofactor Recruitment. <i>Molecular Cell</i> , 1999, 3, 521-526.	9.7	358
7	Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling. <i>Clinical Cancer Research</i> , 2009, 15, 668-676.	7.0	356
8	Transsphenoidal Microsurgery for Cushing's Disease: Initial Outcome and Long-Term Results. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 6348-6357.	3.6	340
9	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. <i>Lancet Oncology</i> , 2015, 16, 426-435.	10.7	272
10	Preclinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 204-212.	3.6	177
11	Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 765-773.	2.3	169
12	Targeted disruption of β -catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. <i>Development (Cambridge)</i> , 2008, 135, 2593-2602.	2.5	168
13	Telomere protection by mammalian Pot1 requires interaction with Tpp1. <i>Nature Structural and Molecular Biology</i> , 2007, 14, 754-761.	8.2	167
14	Recent insights into organogenesis of the adrenal cortex. <i>Trends in Endocrinology and Metabolism</i> , 2002, 13, 200-208.	7.1	161
15	Adjuvant Therapies and Patient and Tumor Characteristics Associated With Survival of Adult Patients With Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 455-461.	3.6	159
16	Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells. <i>Nature</i> , 2010, 466, 769-773.	27.8	157
17	Progression to Adrenocortical Tumorigenesis in Mice and Humans through Insulin-Like Growth Factor 2 and β -Catenin. <i>American Journal of Pathology</i> , 2012, 181, 1017-1033.	3.8	154
18	Adrenocortical Carcinoma Is a Lynch Syndrome-Associated Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3012-3018.	1.6	153

#	ARTICLE	IF	CITATIONS
19	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. <i>European Urology</i> , 2014, 65, 832-838.	1.9	121
20	Minireview: Transcriptional Regulation of Adrenocortical Development. <i>Endocrinology</i> , 2005, 146, 1018-1024.	2.8	120
21	Development of Adrenal Cortex Zonation. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, 243-274.	3.2	116
22	Urogenital and caudal dysgenesis in adrenocortical dysplasia (acd) mice is caused by a splicing mutation in a novel telomeric regulator. <i>Human Molecular Genetics</i> , 2005, 14, 113-123.	2.9	111
23	In Search of Adrenocortical Stem and Progenitor Cells. <i>Endocrine Reviews</i> , 2009, 30, 241-263.	20.1	111
24	Dax-1 and Steroid Receptor RNA Activator (SRA) Function as Transcriptional Coactivators for Steroidogenic Factor 1 in Steroidogenesis. <i>Molecular and Cellular Biology</i> , 2009, 29, 1719-1734.	2.3	104
25	Reciprocal Regulation of a Glucocorticoid Receptor-Steroidogenic Factor-1 Transcription Complex on the Dax-1 Promoter by Glucocorticoids and Adrenocorticotropic Hormone in the Adrenal Cortex. <i>Molecular Endocrinology</i> , 2006, 20, 2711-2723.	3.7	98
26	Steroidogenic Factor-1: Its Role in Endocrine Organ Development and Differentiation. <i>Frontiers in Neuroendocrinology</i> , 1999, 20, 199-223.	5.2	89
27	Genetics and epigenetics of adrenocortical tumors. <i>Molecular and Cellular Endocrinology</i> , 2014, 386, 67-84.	3.2	88
28	Convergence of Wnt Signaling and Steroidogenic Factor-1 (SF-1) on Transcription of the Rat Inhibin β Gene. <i>Journal of Biological Chemistry</i> , 2003, 278, 26572-26579.	3.4	87
29	Genetic analysis of adrenal absence: agenesis and aplasia. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 458-468.	7.1	87
30	Steroidogenic Factor-1 Is Essential for Compensatory Adrenal Growth Following Unilateral Adrenalectomy. <i>Endocrinology</i> , 2002, 143, 3122-3135.	2.8	84
31	Ectopic pro-opiomelanocortin syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2002, 31, 191-234.	3.2	82
32	Prevalence of Germline TP53 Mutations in a Prospective Series of Unselected Patients with Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E119-E125.	3.6	80
33	The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial. <i>Hormones and Cancer</i> , 2014, 5, 232-239.	4.9	79
34	Interaction Between Dax-1 and Steroidogenic Factor-1 in Vivo: Increased Adrenal Responsiveness to ACTH in the Absence of Dax-1. <i>Endocrinology</i> , 2002, 143, 665-673.	2.8	76
35	Molecular Heterogeneity in Aldosterone-Producing Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 999-1007.	3.6	74
36	A ZNRF3-dependent Wnt/ β -catenin signaling gradient is required for adrenal homeostasis. <i>Genes and Development</i> , 2019, 33, 209-220.	5.9	74

#	ARTICLE	IF	CITATIONS
37	Regulation of the adrenocortical stem cell niche: implications for disease. <i>Nature Reviews Endocrinology</i> , 2015, 11, 14-28.	9.6	73
38	Activin Induces x-Zone Apoptosis That Inhibits Luteinizing Hormone-Dependent Adrenocortical Tumor Formation in Inhibin-Deficient Mice. <i>Molecular and Cellular Biology</i> , 2003, 23, 3951-3964.	2.3	72
39	Wnt Signaling Inhibits Adrenal Steroidogenesis by Cell-Autonomous and Non-Cell-Autonomous Mechanisms. <i>Molecular Endocrinology</i> , 2014, 28, 1471-1486.	3.7	72
40	Worsening Central Sarcopenia and Increasing Intra-Abdominal Fat Correlate with Decreased Survival in Patients with Adrenocortical Carcinoma. <i>World Journal of Surgery</i> , 2012, 36, 1509-1516.	1.6	70
41	Fetal adrenal capsular cells serve as progenitor cells for steroidogenic and stromal adrenocortical cell lineages in <i>M. musculus</i> . <i>Development (Cambridge)</i> , 2013, 140, 4522-4532.	2.5	70
42	Adrenocorticotrophic Hormone-Mediated Signaling Cascades Coordinate a Cyclic Pattern of Steroidogenic Factor 1-Dependent Transcriptional Activation. <i>Molecular Endocrinology</i> , 2006, 20, 147-166.	3.7	69
43	T-Cell Factor 4N (TCF-4N), a Novel Isoform of Mouse TCF-4, Synergizes with β -Catenin To Coactivate C/EBP β and Steroidogenic Factor 1 Transcription Factors. <i>Molecular and Cellular Biology</i> , 2003, 23, 5366-5375.	2.3	67
44	Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. <i>Langenbeck's Archives of Surgery</i> , 2010, 395, 955-961.	1.9	65
45	ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs. <i>Endocrinology</i> , 2016, 157, 1775-1788.	2.8	65
46	Abiraterone Acetate to Lower Androgens in Women With Classic 21-Hydroxylase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2763-2770.	3.6	64
47	Sonic Hedgehog and WNT Signaling Promote Adrenal Gland Regeneration in Male Mice. <i>Endocrinology</i> , 2018, 159, 579-596.	2.8	64
48	Adjuvant Radiation Therapy Improves Local Control After Surgical Resection in Patients With Localized Adrenocortical Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 252-259.	0.8	61
49	Origin and Identity of Adrenocortical Tumors in Inhibin Knockout Mice: Implications for Cellular Plasticity in the Adrenal Cortex. <i>Molecular Endocrinology</i> , 2006, 20, 2848-2863.	3.7	60
50	Adrenocortical stem and progenitor cells: Unifying model of two proposed origins. <i>Molecular and Cellular Endocrinology</i> , 2011, 336, 206-212.	3.2	60
51	Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome. <i>European Journal of Endocrinology</i> , 2014, 170, 829-835.	3.7	60
52	Adrenocortical cells with stem/progenitor cell properties: Recent advances. <i>Molecular and Cellular Endocrinology</i> , 2007, 265-266, 10-16.	3.2	59
53	SUMOylation Inhibits SF-1 Activity by Reducing CDK7-Mediated Serine 203 Phosphorylation. <i>Molecular and Cellular Biology</i> , 2009, 29, 613-625.	2.3	59
54	Evidence of Adrenal Failure in Aging Dax1-Deficient Mice. <i>Endocrinology</i> , 2011, 152, 3430-3439.	2.8	56

#	ARTICLE	IF	CITATIONS
55	Genetic Removal of Smad3 from Inhibin-Null Mice Attenuates Tumor Progression by Uncoupling Extracellular Mitogenic Signals from the Cell Cycle Machinery. <i>Molecular Endocrinology</i> , 2007, 21, 2440-2457.	3.7	54
56	Genetic p53 Deficiency Partially Rescues the Adrenocortical Dysplasia Phenotype at the Expense of Increased Tumorigenesis. <i>Cancer Cell</i> , 2009, 15, 465-476.	16.8	53
57	Pituitary-Specific and Hormonally Regulated Gene Expression Directed by the Rat Proopiomelanocortin Promoter in Transgenic Mice. <i>Molecular Endocrinology</i> , 1990, 4, 1689-1697.	3.7	52
58	The molecular genetics of adrenocortical carcinoma. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2007, 8, 343-348.	5.7	52
59	Dax1 Up-Regulates Oct4 Expression in Mouse Embryonic Stem Cells via LRH-1 and SRA. <i>Molecular Endocrinology</i> , 2010, 24, 2281-2291.	3.7	52
60	Targeted Assessment of GOS2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 3276-3288.	7.0	51
61	Hedgehog Signaling and Steroidogenesis. <i>Annual Review of Physiology</i> , 2015, 77, 105-129.	13.1	50
62	Longitudinal patterns of recurrence in patients with adrenocortical carcinoma. <i>Surgery</i> , 2019, 165, 186-195.	1.9	47
63	Evaluation of Telomere Length Maintenance Mechanisms in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1442-1449.	3.6	45
64	GSK3 β and β -Catenin Modulate Radiation Cytotoxicity in Pancreatic Cancer. <i>Neoplasia</i> , 2010, 12, 357-365.	5.3	43
65	Adrenocortical stem and progenitor cells: Implications for adrenocortical carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 2-11.	3.2	43
66	Mebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma. <i>Endocrine Practice</i> , 2011, 17, e59-e62.	2.1	39
67	Therapeutic Targets for Adrenocortical Carcinoma in the Genomics Era. <i>Journal of the Endocrine Society</i> , 2018, 2, 1259-1274.	0.2	38
68	Tpp1/Acd maintains genomic stability through a complex role in telomere protection. <i>Chromosome Research</i> , 2007, 15, 1001-1013.	2.2	37
69	Double adrenocortical adenomas harboring independent KCNJ5 and PRKACA somatic mutations. <i>European Journal of Endocrinology</i> , 2016, 175, K1-K6.	3.7	37
70	Inhibin-A Antagonizes TGF β 2 Signaling by Down-Regulating Cell Surface Expression of the TGF β 2 Coreceptor Betaglycan. <i>Molecular Endocrinology</i> , 2010, 24, 608-620.	3.7	36
71	Adjuvant Radiation Improves Recurrence-Free Survival and Overall Survival in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3743-3750.	3.6	35
72	Gonadectomy in mice of the inbred strain CE/J induces proliferation of sub-capsular adrenal cells expressing gonadal marker genes. <i>Journal of Endocrinology</i> , 2006, 190, 47-57.	2.6	34

#	ARTICLE	IF	CITATIONS
73	Upregulated JAG1 Enhances Cell Proliferation in Adrenocortical Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 2452-2464.	7.0	33
74	What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics. <i>Endocrine Pathology</i> , 2021, 32, 102-133.	9.0	33
75	LRH-1 and Nanog regulate Dax1 transcription in mouse embryonic stem cells. <i>Molecular and Cellular Endocrinology</i> , 2011, 332, 116-124.	3.2	31
76	The effects of naloxone administered into the periaqueductal gray on shock-elicited freezing behavior in the rat. <i>Behavioral and Neural Biology</i> , 1986, 46, 189-195.	2.2	29
77	POD-1 binding to the E-box sequence inhibits SF-1 and StAR expression in human adrenocortical tumor cells. <i>Molecular and Cellular Endocrinology</i> , 2013, 371, 140-147.	3.2	28
78	Dicer Deficiency Reveals MicroRNAs Predicted to Control Gene Expression in the Developing Adrenal Cortex. <i>Molecular Endocrinology</i> , 2013, 27, 754-768.	3.7	27
79	Withanolides are Potent Novel Targeted Therapeutic Agents Against Adrenocortical Carcinomas. <i>World Journal of Surgery</i> , 2014, 38, 1343-1352.	1.6	24
80	Interaction Between Dax-1 and Steroidogenic Factor-1 in Vivo: Increased Adrenal Responsiveness to ACTH in the Absence of Dax-1. <i>Endocrinology</i> , 2002, 143, 665-673.	2.8	24
81	Adrenocortical carcinoma and succinate dehydrogenase gene mutations: an observational case series. <i>European Journal of Endocrinology</i> , 2017, 177, 439-444.	3.7	23
82	Cell signaling pathways in the adrenal cortex: Links to stem/progenitor biology and neoplasia. <i>Molecular and Cellular Endocrinology</i> , 2017, 445, 42-54.	3.2	21
83	Timing of adrenal regression controlled by synergistic interaction between Sf1 SUMOylation and Dax1. <i>Development (Cambridge)</i> , 2017, 144, 3798-3807.	2.5	18
84	Steroidogenic Factor-1 Is Essential for Compensatory Adrenal Growth Following Unilateral Adrenalectomy. <i>Endocrinology</i> , 2002, 143, 3122-3135.	2.8	18
85	Stem cell function and plasticity in the normal physiology of the adrenal cortex. <i>Molecular and Cellular Endocrinology</i> , 2021, 519, 111043.	3.2	15
86	An oncocytic adrenal tumour in a patient with Birt-Hogg-Keeler syndrome. <i>Clinical Endocrinology</i> , 2014, 80, 925-927.	2.4	14
87	Mouse models of adrenocortical tumors. <i>Molecular and Cellular Endocrinology</i> , 2016, 421, 82-97.	3.2	13
88	Aged PROP1 Deficient Dwarf Mice Maintain ACTH Production. <i>PLoS ONE</i> , 2011, 6, e28355.	2.5	13
89	Role of Phosphorylation, Gene Dosage and Dax-1 in SF-1 Mediated Steroidogenesis. <i>Endocrine Research</i> , 2000, 26, 985-994.	1.2	12
90	IMAGe association and congenital adrenal hypoplasia: No disease-causing mutations found in the ACD gene. <i>Molecular Genetics and Metabolism</i> , 2006, 88, 66-70.	1.1	12

#	ARTICLE	IF	CITATIONS
91	Nutritional conditions regulate transcriptional activity of SF-1 by controlling sumoylation and ubiquitination. <i>Scientific Reports</i> , 2016, 6, 19143.	3.3	12
92	Somatic mutations in adrenocortical carcinoma with primary aldosteronism or hyperreninemic hyperaldosteronism. <i>Endocrine-Related Cancer</i> , 2019, 26, 217-225.	3.1	10
93	Targeted RNAseq of Formalin-Fixed Paraffin-Embedded Tissue to Differentiate Among Benign and Malignant Adrenal Cortical Tumors. <i>Hormone and Metabolic Research</i> , 2020, 52, 607-613.	1.5	9
94	β-catenin in adrenal zonation and disease. <i>Molecular and Cellular Endocrinology</i> , 2021, 522, 111120.	3.2	9
95	Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies. <i>Endocrine Reviews</i> , 2022, 43, 1051-1073.	20.1	9
96	Management of Adrenocortical Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 752-759.	4.9	8
97	Regulation of stem and progenitor cells in the adrenal cortex. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 8, 66-71.	1.4	7
98	New strategies for applying targeted therapies to adrenocortical carcinoma. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 8, 72-79.	1.4	6
99	Novel polymorphisms and lack of mutations in the ACD gene in patients with ACTH resistance syndromes. <i>Clinical Endocrinology</i> , 2007, 67, 168-174.	2.4	5
100	Mechanistic Roles of Inhibin as a Tumor Suppressor in the Adrenal Cortex. <i>Endocrine Research</i> , 2004, 30, 585-586.	1.2	4
101	Isolation, Fixation, and Immunofluorescence Imaging of Mouse Adrenal Glands. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	4
102	Adrenal Cancer: Scientific Advances. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 1.	3.2	2
103	Abstract 2976: Comprehensive Pan-Genomic characterization of adrenocortical carcinoma. , 2015, , .		2
104	Drug repurposing using high-throughput screening identifies a promising drug combination to treat adrenocortical carcinoma. <i>Oncotarget</i> , 2018, 9, 33245-33246.	1.8	2
105	Adrenal Cancer: Clinical Advances. <i>Hormones and Cancer</i> , 2011, 2, 323-323.	4.9	1
106	Adrenal Development. , 2014, , 5-27.		1
107	An interview with Gary D Hammer, MD, PhD. <i>International Journal of Endocrine Oncology</i> , 2019, 6, IJE23.	0.4	1
108	Gary D Hammer on the improvement of patient care in endocrine neoplasia. <i>International Journal of Endocrine Oncology</i> , 2019, 6, IJE24.	0.4	1

#	ARTICLE	IF	CITATIONS
109	SAT-LB34 Repressive Epigenetic Programs Reinforce Steroidogenic Differentiation and Wnt/ β 2-Catenin Signaling in Aggressive Adrenocortical Carcinoma. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	1
110	Raging Hormones in Development and Cancer. <i>Cell</i> , 1999, 96, 476-477.	28.9	0
111	Genetics of Adrenal Tumors. , 2014, , 313-321.		0
112	Adrenocortical Stem and Progenitor Cells: Implications for Cancer. , 2009, , 285-304.		0